Klin Farmakol Farm. 2015;29(2):84-86

Current application of rituximab in pharmacotherapy

Dana Syrová
Nemocniční lékárna VFN Praha

Rituximab is the first registered monoclonal antibody in the treatment of hematologic malignancies. It binds to the surface of B-lymphocytes

that have CD20 antigen on the surface. It was approved by the FDA (Food and Drug Administration) in 1997 for the treatment

of relapsing or refractory follicular lymphoma. The results of further investigations extended its indication to other specialities such as

rheumatology and nephrology. Its introduction in the practice represented a turning point in the treatment and changed the patients’

fate, particularly due to its minimal toxicity and higher effect specificity. Targeted monoclonal antibody therapy has now become

a regular (standard) part of medical practice in a variety of diseases.

Keywords: rituximab, monoclonal antibodies, CD20, B-lymphocyte

Published: July 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Syrová D. Current application of rituximab in pharmacotherapy. Klin Farmakol Farm. 2015;29(2):84-86.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kohler G, Milstein C. Continnuoscultures off used cells secreting antibody of predefined specifity. Nature 1975; 256: 495-497. Go to original source... Go to PubMed...
    2. Papajík T, Faber E, Indrák K. Nové směry a perspektivy v léčbě hematologických malignit. Interní Med 2003; 2: 71-77.
    3. Belada D. Monoklonální protilátky v léčbě lymfomů. Remedia 2008; 18(6): 416-423.
    4. Vášová I, Mayer J, Navrátil M. Rituximab v léčbě lymfoproliferativních onemocnění. Trendy ve farmakoterapii. Příloha Zdravotnických novin 2002; 3: 7-9.
    5. McLaughlin P. Rituximab perspective on single agent experience and future directions in combination trials. Crit Rev Oncol Hematol 2001; 40: 3-16. Go to original source... Go to PubMed...
    6. EMEA, http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-Product_Information/human/000165/WC500025821.pdf, přistoupeno 22. 2. 2015.
    7. Pavelka K. Rituximab v léčbě revmatoidní artritidy. Remedia 2007; 17: 440-447.
    8. Bečvář R, Vencovský J, Němec P, Suchý D, Procházková L, Pavelka K. Doporučení České revmatologické společnosti pro léčbu revmatické artritidy. Účinnost a strategie léčby. Česrevmatol 2007; 15: 73-90.
    9. Rule S, Collins G, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. Journal of Medical Economics 2014; 17(7): 459-468. Go to original source... Go to PubMed...
    10. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 2013; 109: 1556-1561. Go to original source... Go to PubMed...
    11. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, Mcintyre Ch, MacDonald D. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet oncol 2014; 15: 343-352. Go to original source... Go to PubMed...
    12. Ryšavá R. Možnosti použití biologické léčby u nemocných s glomerulárními chorobami. Urologie praxi 2012; 13(6): 246-252.
    13. Strojil J, Ciferská H. Vybrané aktuality v indikacích imunosupresiv. Interní Med 2009; 11(9): 402-404.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.